<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04322396</url>
  </required_header>
  <id_info>
    <org_study_id>KronLungesyg_COVID_19_protokol</org_study_id>
    <nct_id>NCT04322396</nct_id>
  </id_info>
  <brief_title>Proactive Protection With Azithromycin and hydroxyChloroquine in Hospitalized Patients With COVID-19</brief_title>
  <acronym>ProPAC-COVID</acronym>
  <official_title>Proactive Protection With Azithromycin and Hydroxychloroquine in Hospitalized Patients With COVID: A Randomized, Placebo-controlled Double-blinded Trial Evaluating Treatment With Azithromycin and Hydroxychloroquine to Patients With COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chronic Obstructive Pulmonary Disease Trial Network, Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chronic Obstructive Pulmonary Disease Trial Network, Denmark</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study explores whether patients acutely hospitalized may have shorter hospitalization&#xD;
      and fewer admittances at Intensive Care Units by treatment with azithromycin and&#xD;
      hydroxychloroquine.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the ongoing coronavirus pandemic, COVID-19, that arose in Wuhan China, there is still&#xD;
      sparse data in the course, risk of various complications, and in particular how patients who&#xD;
      are hospitalized are best treated to ensure high survival and short hospitalization. Despite&#xD;
      the rapid spread of the disease globally, there is no solid data yet to recommend any&#xD;
      specific treatments, which is why symptomatic, organ supportive therapy including respiratory&#xD;
      therapy in acute pulmonary failure is recommended. There has been reported a high incidence&#xD;
      of bacterial super-infections in patients with COVID-19. Patients with COVID-19 also have a&#xD;
      higher risk of dying because of septic shock. Thus, there is an urgent need for treatment&#xD;
      that can improve the patient's chance of the shortest hospitalization possible, and treatment&#xD;
      that can lower the risk of secondary infection and death.&#xD;
&#xD;
      This is a randomized, placebo-controlled, double-blinded multi-center trial evaluating the&#xD;
      effect of azithromycin and hydroxychloroquine treatment in patients with COVID-19 during&#xD;
      hospitalization. The aim of the study is to investigate whether the treatment can shorten&#xD;
      hospitalization, reduce the risk of non-invasive ventilation, admittance to Intensive Care&#xD;
      Units and death.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Recommended by the DSMB&#xD;
  </why_stopped>
  <start_date type="Actual">April 6, 2020</start_date>
  <completion_date type="Actual">February 2, 2021</completion_date>
  <primary_completion_date type="Actual">February 2, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Days Alive and Discharged From Hospital Within 14 Days</measure>
    <time_frame>14 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Categorization of Hospitalization Status</measure>
    <time_frame>14 days</time_frame>
    <description>The patient will be categorized into one of the following 8 categories depending on status of their hospitalization:&#xD;
Dead (yes/no)&#xD;
Hospitalized and receiving mechanical ventilation or ExtraCorporalMembraneOxygenation (ECMO) (yes/no)&#xD;
Hospitalized and receiving Non-invasive ventilation or &quot;high-flow oxygen device&quot; (yes/no)&#xD;
Hospitalized and given oxygen supplements different from (2) and (3) (yes/no)&#xD;
Hospitalized and without oxygen treatment, but receiving other treatment (both related to COVID-19 or other) (yes/no)&#xD;
Hospitalized for observation (yes/no)&#xD;
Discharged from hospital with restriction of activity level (yes/no)&#xD;
Discharged from hospital without any restrictions of activity level (yes/no)&#xD;
Only one category can be &quot;yes&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of Stay in ICU</measure>
    <time_frame>14 days</time_frame>
    <description>Length of stay in intensive care unit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants on Non-invasive Ventilation (NIV) During Hospitalization</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of Hospitalization</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days Alive and Discharged From Hospital</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>365 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Readmissions (All Causes)</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Days Using Non-invasive Ventilation (NIV)</measure>
    <time_frame>14 days</time_frame>
    <description>Number of days using non-invasive ventilation (NIV) if on NIV during hospitalization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Patient's Oxygen Partial Pressure</measure>
    <time_frame>4 days</time_frame>
    <description>PaO2 measured in arterial puncture at baseline and 4 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Patient's Carbondioxide Partial Pressure</measure>
    <time_frame>4 days</time_frame>
    <description>PaCO2 measured in arterial puncture at baseline and 4 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of pH in Blood</measure>
    <time_frame>4 days</time_frame>
    <description>pH measured in arterial puncture at baseline and 4 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time for no Oxygen Supplement (or Regular Oxygen Supplement &quot;LTOT&quot;)</measure>
    <time_frame>14 days</time_frame>
    <description>Time for no oxygen supplement (or regular oxygen supplement &quot;LTOT&quot;) if on oxygen during admission.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">117</enrollment>
  <condition>Virus Diseases</condition>
  <condition>Infection Viral</condition>
  <condition>Corona Virus Infection</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>This arm will receive standard care and placebo in 15 days.&#xD;
Azithromycin placebo:&#xD;
Day 1-3: 500 mg x 1 Day 4-15: 250 mg x 1&#xD;
Hydroxychloroquine placebo:&#xD;
Day 1-15: 200 mg x 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This arm will receive standard care and azithromycin and hydroxychloroquine in 15 days.&#xD;
Azithromycin:&#xD;
Day 1-3: 500 mg x 1 Day 4-15: 250 mg x 1&#xD;
Hydroxychloroquine:&#xD;
Day 1-15: 200 mg x 2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azithromycin</intervention_name>
    <description>Azithromycin</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroxychloroquine</intervention_name>
    <description>Hydroxychloroquine</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral tablet</intervention_name>
    <description>Placebo Azithromycin</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral tablet</intervention_name>
    <description>Placebo Hydroxychloroquine</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient admitted to a Danish emergency department, lung medical department or medical&#xD;
             department&#xD;
&#xD;
          -  Age &gt;18 years&#xD;
&#xD;
          -  Hospitalized &lt;48 hours&#xD;
&#xD;
          -  Positive COVID-19 test/diagnosis during the hospitalization&#xD;
&#xD;
          -  Signs informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  If the patient uses &gt; 5 LO2/min at time of recruitment&#xD;
&#xD;
          -  Known intolerance/allergy to azithromycin or hydroxychloroquine or hypersensitivity to&#xD;
             quinine or 4-aminoquinolinderivates&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Breastfeeding&#xD;
&#xD;
          -  Neurogenic hearing loss&#xD;
&#xD;
          -  Psoriasis&#xD;
&#xD;
          -  Retinopathy&#xD;
&#xD;
          -  Maculopathy&#xD;
&#xD;
          -  Changes in vision field&#xD;
&#xD;
          -  Severe liver disease other than amoebiases&#xD;
&#xD;
          -  Severe gastrointestinal, neurological or haematological disorders&#xD;
&#xD;
          -  eGFR &lt; 45 ml/min/1.73m2&#xD;
&#xD;
          -  Clinically significant cardiac conduction disorders/arrhythmias or prolonged QTc&#xD;
             interval&#xD;
&#xD;
          -  Myasthenia Gravis&#xD;
&#xD;
          -  Uses Digoxin&#xD;
&#xD;
          -  Glucose-6-phosphate dehydrogenase deficiency&#xD;
&#xD;
          -  Porphyria&#xD;
&#xD;
          -  Hypoglycemia at any time since hospitalization&#xD;
&#xD;
          -  Severe mental illness which significantly impedes cooperation&#xD;
&#xD;
          -  Severe linguistic problems that significantly impedes cooperation&#xD;
&#xD;
          -  Treatment with sickle alkaloids&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Aalborg Sygehus</name>
      <address>
        <city>Aalborg</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bispebjerg Hospital</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herlev-Gentofte Hospital</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hvidovre Hospital</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nordsjællands Hospital</name>
      <address>
        <city>Hillerød</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Odense Universitetshospital</name>
      <address>
        <city>Odense</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roskilde Sygehus</name>
      <address>
        <city>Roskilde</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Slagelse Sygehus</name>
      <address>
        <city>Slagelse</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>March 23, 2020</study_first_submitted>
  <study_first_submitted_qc>March 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 26, 2020</study_first_posted>
  <results_first_submitted>June 15, 2021</results_first_submitted>
  <results_first_submitted_qc>June 24, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">June 28, 2021</results_first_posted>
  <last_update_submitted>June 28, 2021</last_update_submitted>
  <last_update_submitted_qc>June 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
    <mesh_term>Coronavirus Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azithromycin</mesh_term>
    <mesh_term>Hydroxychloroquine</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 16, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/96/NCT04322396/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 19, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/96/NCT04322396/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Control</title>
          <description>This arm will receive standard care and placebo in 15 days.&#xD;
Placebo oral tablet: Placebo Azithromycin&#xD;
Placebo oral tablet: Placebo Hydroxychloroquine</description>
        </group>
        <group group_id="P2">
          <title>Intervention</title>
          <description>This arm will receive standard care and azithromycin and hydroxychloroquine in 15 days.&#xD;
Azithromycin: Azithromycin&#xD;
Hydroxychloroquine: Hydroxychloroquine</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="56"/>
                <participants group_id="P2" count="61"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="56"/>
                <participants group_id="P2" count="61"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Control</title>
          <description>This arm will receive standard care and placebo in 15 days.&#xD;
Placebo oral tablet: Placebo Azithromycin&#xD;
Placebo oral tablet: Placebo Hydroxychloroquine</description>
        </group>
        <group group_id="B2">
          <title>Intervention</title>
          <description>This arm will receive standard care and azithromycin and hydroxychloroquine in 15 days.&#xD;
Azithromycin: Azithromycin&#xD;
Hydroxychloroquine: Hydroxychloroquine</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="56"/>
            <count group_id="B2" value="61"/>
            <count group_id="B3" value="117"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63" lower_limit="52" upper_limit="74"/>
                    <measurement group_id="B2" value="68" lower_limit="52" upper_limit="80"/>
                    <measurement group_id="B3" value="65" lower_limit="52" upper_limit="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="52"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Race/ethnicity</title>
              <category_list>
                <category>
                  <title>Caucasian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="98"/>
                  </measurement_list>
                </category>
                <category>
                  <title>African</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown/other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Denmark</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Days Alive and Discharged From Hospital Within 14 Days</title>
        <time_frame>14 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>This arm will receive standard care and placebo in 15 days.&#xD;
Placebo oral tablet: Placebo Azithromycin&#xD;
Placebo oral tablet: Placebo Hydroxychloroquine</description>
          </group>
          <group group_id="O2">
            <title>Intervention</title>
            <description>This arm will receive standard care and azithromycin and hydroxychloroquine in 15 days.&#xD;
Azithromycin: Azithromycin&#xD;
Hydroxychloroquine: Hydroxychloroquine</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Days Alive and Discharged From Hospital Within 14 Days</title>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9" lower_limit="7" upper_limit="10"/>
                    <measurement group_id="O2" value="9" lower_limit="3" upper_limit="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Categorization of Hospitalization Status</title>
        <description>The patient will be categorized into one of the following 8 categories depending on status of their hospitalization:&#xD;
Dead (yes/no)&#xD;
Hospitalized and receiving mechanical ventilation or ExtraCorporalMembraneOxygenation (ECMO) (yes/no)&#xD;
Hospitalized and receiving Non-invasive ventilation or &quot;high-flow oxygen device&quot; (yes/no)&#xD;
Hospitalized and given oxygen supplements different from (2) and (3) (yes/no)&#xD;
Hospitalized and without oxygen treatment, but receiving other treatment (both related to COVID-19 or other) (yes/no)&#xD;
Hospitalized for observation (yes/no)&#xD;
Discharged from hospital with restriction of activity level (yes/no)&#xD;
Discharged from hospital without any restrictions of activity level (yes/no)&#xD;
Only one category can be &quot;yes&quot;.</description>
        <time_frame>14 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>This arm will receive standard care and placebo in 15 days.&#xD;
Placebo oral tablet: Placebo Azithromycin&#xD;
Placebo oral tablet: Placebo Hydroxychloroquine</description>
          </group>
          <group group_id="O2">
            <title>Intervention</title>
            <description>This arm will receive standard care and azithromycin and hydroxychloroquine in 15 days.&#xD;
Azithromycin: Azithromycin&#xD;
Hydroxychloroquine: Hydroxychloroquine</description>
          </group>
        </group_list>
        <measure>
          <title>Categorization of Hospitalization Status</title>
          <description>The patient will be categorized into one of the following 8 categories depending on status of their hospitalization:&#xD;
Dead (yes/no)&#xD;
Hospitalized and receiving mechanical ventilation or ExtraCorporalMembraneOxygenation (ECMO) (yes/no)&#xD;
Hospitalized and receiving Non-invasive ventilation or &quot;high-flow oxygen device&quot; (yes/no)&#xD;
Hospitalized and given oxygen supplements different from (2) and (3) (yes/no)&#xD;
Hospitalized and without oxygen treatment, but receiving other treatment (both related to COVID-19 or other) (yes/no)&#xD;
Hospitalized for observation (yes/no)&#xD;
Discharged from hospital with restriction of activity level (yes/no)&#xD;
Discharged from hospital without any restrictions of activity level (yes/no)&#xD;
Only one category can be &quot;yes&quot;.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Dead</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Hospitalized and receiving mechanical ventilation or ExtraCorporalMembraneOxygenation (ECMO)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Hospitalized and receiving Non-invasive ventilation or &quot;high-flow oxygen device&quot;</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Hospitalized and given oxygen supplements different from (2) and (3)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Hospitalized and without oxygen, but receiving other treatment (both related to COVID-19 or other)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Hospitalized for observation</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Discharged from hospital with restriction of activity level</title>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Discharged from hospital without any restrictions of activity level</title>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Length of Stay in ICU</title>
        <description>Length of stay in intensive care unit.</description>
        <time_frame>14 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>This arm will receive standard care and placebo in 15 days.&#xD;
Placebo oral tablet: Placebo Azithromycin&#xD;
Placebo oral tablet: Placebo Hydroxychloroquine</description>
          </group>
          <group group_id="O2">
            <title>Intervention</title>
            <description>This arm will receive standard care and azithromycin and hydroxychloroquine in 15 days.&#xD;
Azithromycin: Azithromycin&#xD;
Hydroxychloroquine: Hydroxychloroquine</description>
          </group>
        </group_list>
        <measure>
          <title>Length of Stay in ICU</title>
          <description>Length of stay in intensive care unit.</description>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11" lower_limit="4" upper_limit="14"/>
                    <measurement group_id="O2" value="14" lower_limit="9.5" upper_limit="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants on Non-invasive Ventilation (NIV) During Hospitalization</title>
        <time_frame>14 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>This arm will receive standard care and placebo in 15 days.&#xD;
Placebo oral tablet: Placebo Azithromycin&#xD;
Placebo oral tablet: Placebo Hydroxychloroquine</description>
          </group>
          <group group_id="O2">
            <title>Intervention</title>
            <description>This arm will receive standard care and azithromycin and hydroxychloroquine in 15 days.&#xD;
Azithromycin: Azithromycin&#xD;
Hydroxychloroquine: Hydroxychloroquine</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants on Non-invasive Ventilation (NIV) During Hospitalization</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mortality</title>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>This arm will receive standard care and placebo in 15 days.&#xD;
Placebo oral tablet: Placebo Azithromycin&#xD;
Placebo oral tablet: Placebo Hydroxychloroquine</description>
          </group>
          <group group_id="O2">
            <title>Intervention</title>
            <description>This arm will receive standard care and azithromycin and hydroxychloroquine in 15 days.&#xD;
Azithromycin: Azithromycin&#xD;
Hydroxychloroquine: Hydroxychloroquine</description>
          </group>
        </group_list>
        <measure>
          <title>Mortality</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Length of Hospitalization</title>
        <time_frame>14 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>This arm will receive standard care and placebo in 15 days.&#xD;
Placebo oral tablet: Placebo Azithromycin&#xD;
Placebo oral tablet: Placebo Hydroxychloroquine</description>
          </group>
          <group group_id="O2">
            <title>Intervention</title>
            <description>This arm will receive standard care and azithromycin and hydroxychloroquine in 15 days.&#xD;
Azithromycin: Azithromycin&#xD;
Hydroxychloroquine: Hydroxychloroquine</description>
          </group>
        </group_list>
        <measure>
          <title>Length of Hospitalization</title>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="3" upper_limit="6"/>
                    <measurement group_id="O2" value="4" lower_limit="2" upper_limit="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Days Alive and Discharged From Hospital</title>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>This arm will receive standard care and placebo in 15 days.&#xD;
Placebo oral tablet: Placebo Azithromycin&#xD;
Placebo oral tablet: Placebo Hydroxychloroquine</description>
          </group>
          <group group_id="O2">
            <title>Intervention</title>
            <description>This arm will receive standard care and azithromycin and hydroxychloroquine in 15 days.&#xD;
Azithromycin: Azithromycin&#xD;
Hydroxychloroquine: Hydroxychloroquine</description>
          </group>
        </group_list>
        <measure>
          <title>Days Alive and Discharged From Hospital</title>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26" lower_limit="23" upper_limit="27"/>
                    <measurement group_id="O2" value="26" lower_limit="21" upper_limit="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mortality</title>
        <time_frame>90 days</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mortality</title>
        <time_frame>365 days</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Readmissions (All Causes)</title>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>This arm will receive standard care and placebo in 15 days.&#xD;
Placebo oral tablet: Placebo Azithromycin&#xD;
Placebo oral tablet: Placebo Hydroxychloroquine</description>
          </group>
          <group group_id="O2">
            <title>Intervention</title>
            <description>This arm will receive standard care and azithromycin and hydroxychloroquine in 15 days.&#xD;
Azithromycin: Azithromycin&#xD;
Hydroxychloroquine: Hydroxychloroquine</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Readmissions (All Causes)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Days Using Non-invasive Ventilation (NIV)</title>
        <description>Number of days using non-invasive ventilation (NIV) if on NIV during hospitalization.</description>
        <time_frame>14 days</time_frame>
        <population>The Overall Number of Participants Analyzed represents the number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>This arm will receive standard care and placebo in 15 days.&#xD;
Placebo oral tablet: Placebo Azithromycin&#xD;
Placebo oral tablet: Placebo Hydroxychloroquine</description>
          </group>
          <group group_id="O2">
            <title>Intervention</title>
            <description>This arm will receive standard care and azithromycin and hydroxychloroquine in 15 days.&#xD;
Azithromycin: Azithromycin&#xD;
Hydroxychloroquine: Hydroxychloroquine</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Days Using Non-invasive Ventilation (NIV)</title>
          <description>Number of days using non-invasive ventilation (NIV) if on NIV during hospitalization.</description>
          <population>The Overall Number of Participants Analyzed represents the number of participants with available data.</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.0" lower_limit="NA" upper_limit="NA">Only 1 patient on NIV in this group.</measurement>
                    <measurement group_id="O2" value="6.7" lower_limit="-9.1" upper_limit="22.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Patient's Oxygen Partial Pressure</title>
        <description>PaO2 measured in arterial puncture at baseline and 4 days.</description>
        <time_frame>4 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>This arm will receive standard care and placebo in 15 days.&#xD;
Placebo oral tablet: Placebo Azithromycin&#xD;
Placebo oral tablet: Placebo Hydroxychloroquine</description>
          </group>
          <group group_id="O2">
            <title>Intervention</title>
            <description>This arm will receive standard care and azithromycin and hydroxychloroquine in 15 days.&#xD;
Azithromycin: Azithromycin&#xD;
Hydroxychloroquine: Hydroxychloroquine</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Patient's Oxygen Partial Pressure</title>
          <description>PaO2 measured in arterial puncture at baseline and 4 days.</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" lower_limit="-8.3" upper_limit="7.8"/>
                    <measurement group_id="O2" value="-3.0" lower_limit="-9.8" upper_limit="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Patient's Carbondioxide Partial Pressure</title>
        <description>PaCO2 measured in arterial puncture at baseline and 4 days.</description>
        <time_frame>4 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>This arm will receive standard care and placebo in 15 days.&#xD;
Placebo oral tablet: Placebo Azithromycin&#xD;
Placebo oral tablet: Placebo Hydroxychloroquine</description>
          </group>
          <group group_id="O2">
            <title>Intervention</title>
            <description>This arm will receive standard care and azithromycin and hydroxychloroquine in 15 days.&#xD;
Azithromycin: Azithromycin&#xD;
Hydroxychloroquine: Hydroxychloroquine</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Patient's Carbondioxide Partial Pressure</title>
          <description>PaCO2 measured in arterial puncture at baseline and 4 days.</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" lower_limit="-0.4" upper_limit="3.3"/>
                    <measurement group_id="O2" value="-3.0" lower_limit="-9.8" upper_limit="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change of pH in Blood</title>
        <description>pH measured in arterial puncture at baseline and 4 days.</description>
        <time_frame>4 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>This arm will receive standard care and placebo in 15 days.&#xD;
Placebo oral tablet: Placebo Azithromycin&#xD;
Placebo oral tablet: Placebo Hydroxychloroquine</description>
          </group>
          <group group_id="O2">
            <title>Intervention</title>
            <description>This arm will receive standard care and azithromycin and hydroxychloroquine in 15 days.&#xD;
Azithromycin: Azithromycin&#xD;
Hydroxychloroquine: Hydroxychloroquine</description>
          </group>
        </group_list>
        <measure>
          <title>Change of pH in Blood</title>
          <description>pH measured in arterial puncture at baseline and 4 days.</description>
          <units>pH</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-0.02" upper_limit="0.01"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-0.03" upper_limit="0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time for no Oxygen Supplement (or Regular Oxygen Supplement &quot;LTOT&quot;)</title>
        <description>Time for no oxygen supplement (or regular oxygen supplement &quot;LTOT&quot;) if on oxygen during admission.</description>
        <time_frame>14 days</time_frame>
        <population>The Overall Number of Participants Analyzed represents the number of participants with available data</population>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>This arm will receive standard care and placebo in 15 days.&#xD;
Placebo oral tablet: Placebo Azithromycin&#xD;
Placebo oral tablet: Placebo Hydroxychloroquine</description>
          </group>
          <group group_id="O2">
            <title>Intervention</title>
            <description>This arm will receive standard care and azithromycin and hydroxychloroquine in 15 days.&#xD;
Azithromycin: Azithromycin&#xD;
Hydroxychloroquine: Hydroxychloroquine</description>
          </group>
        </group_list>
        <measure>
          <title>Time for no Oxygen Supplement (or Regular Oxygen Supplement &quot;LTOT&quot;)</title>
          <description>Time for no oxygen supplement (or regular oxygen supplement &quot;LTOT&quot;) if on oxygen during admission.</description>
          <population>The Overall Number of Participants Analyzed represents the number of participants with available data</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72" lower_limit="39.75" upper_limit="96"/>
                    <measurement group_id="O2" value="72" lower_limit="24" upper_limit="192"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were recorded during the period beginning when the patient received their first dose of trial medication up to and including day 15. All-Cause Mortality was assessed up to 30 days.</time_frame>
      <desc>A serious adverse event (SAE) was defined as an event or adverse event that, regardless of dose, was life-threatening, resulted in significant or persistent disability or incapacity, or led to a congenital anomaly or malformation.&#xD;
Because comorbidities and mortality are common in this patient group, prolonged admission, re-admission, non-invasive ventilation, invasive respiratory treatment and death were not considered SAEs.</desc>
      <group_list>
        <group group_id="E1">
          <title>Control</title>
          <description>This arm will receive standard care and placebo in 15 days.&#xD;
Placebo oral tablet: Placebo Azithromycin&#xD;
Placebo oral tablet: Placebo Hydroxychloroquine</description>
        </group>
        <group group_id="E2">
          <title>Intervention</title>
          <description>This arm will receive standard care and azithromycin and hydroxychloroquine in 15 days.&#xD;
Azithromycin: Azithromycin&#xD;
Hydroxychloroquine: Hydroxychloroquine</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Ventricular arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Hearing loss</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Prolonged QTc</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Photophobia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Itching/Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Bleeding</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Early termination based on recommendations from the DSMB leading to small numbers of subjects analyzed.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Prof. Jens-Ulrik Stæhr Jensen, MD PHD</name_or_title>
      <organization>Gentofte Hospital</organization>
      <phone>+4538673057</phone>
      <email>jens.ulrik.jensen@regionh.dk</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

